AmpliMed Starts Phase II Pancreatic Cancer Trial
Posted on: Friday, 2 May 2008, 09:00 CDT
AmpliMed, a cancer therapeutics company, has announced that patient enrollment is underway in a Phase II trial of Amplimexon for injection in combination with gemcitabine in patients with advanced pancreatic cancer.
The multicenter, randomized Phase II trial will evaluate Amplimexon (imexon for injection) plus gemcitabine versus gemcitabine plus placebo in approximately 124 chemotherapy naive patients with metastatic pancreatic cancer.
The purpose of the study is to determine if Amplimexon in combination with gemcitabine could improve overall survival as compared to gemcitabine alone. The study will also evaluate and compare the tolerability and toxicity of the two treatment arms. The trial is opening at clinical sites throughout the US.
Evan Hersh, executive vice president and chief medical officer of AmpliMed, said: "Amplimexon has demonstrated the ability to overcome resistance and offer an improved safety profile when combined with gemcitabine in preclinical studies of pancreatic cancer, and we look forward to evaluating the impact of this treatment in this randomized clinical trial."
Source: Datamonitor
Related Articles
- AmpliMed Corporation Announces Start of Randomized Phase 2 Trial of Amplimexon in Pancreatic Cancer
- Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
- GTx Initiates Phase IIb Ostarine Clinical Trial For Cancer Cachexia
- Antisense Oligonucleotides Have Been in Clinical Trials for Cancer for Some Time Now - Drug Delivery in Cancer - Technologies, Markets and Companies Report 2007
- Threshold Pharmaceuticals Announces Change in Guidance for Release of Phase 3 Trial Results in Pancreatic Cancer
- Norwood Abbey Announces Phase II Clinical Trial in Cancer Patients Commences
- European Committee for Orphan Medical Products Recommends Orphan Drug Status for AmpliMed's Amplimexon for Pancreatic Cancer
- SuperGen Initiates Phase II Combination Trial of Orathecin(TM) and Gemcitabine in Chemotherapy Naive Pancreatic Cancer Patients
- Vion Provides Update on Triapine(R)-Gemcitabine Trial in Pancreatic Cancer
- Internalization of Luminescent Calcium Phosphate Nanoparticles By Human Cancerous Pancreatic Ductal Cells (Capan-1 Line)
 |
 |
User Comments (0)
RSS Feeds